Six IPOs raised $1.8 billion ahead of the short holiday week, joined by one direct listing and five SPACs. Returns bounced back after tumultuous trading earlier this month, with the week’s deals all finishing above issue. New filers began to flood the...read more
Day One Biopharmaceuticals, a Phase 2 biotech developing kinase inhibitors for pediatric brain tumors, raised $160 million by offering 10 million shares at $16, the high end of the range of $14 to $16. The company originally planned to offer 8.4 million shares...read more
Day One Biopharmaceuticals, a Phase 2 biotech developing kinase inhibitors for pediatric brain tumors, raised the proposed deal size for its upcoming IPO on Wednesday. The South San Francisco, CA-based company now plans to raise $150 million by offering 10...read more
Day One Biopharmaceuticals, a Phase 2 biotech developing treatments for pediatric glioma and other cancers, announced terms for its IPO on Monday. The South San Francisco, CA-based company plans to raise $126 million by offering 8.4 million shares at a...read more
US IPO Weekly Recap: Returns bounce back in a 6 IPO, 1 direct listing week
Six IPOs raised $1.8 billion ahead of the short holiday week, joined by one direct listing and five SPACs. Returns bounced back after tumultuous trading earlier this month, with the week’s deals all finishing above issue. New filers began to flood the...read more
Pediatric cancer biotech Day One Biopharmaceuticals prices IPO at $16 high end
Day One Biopharmaceuticals, a Phase 2 biotech developing kinase inhibitors for pediatric brain tumors, raised $160 million by offering 10 million shares at $16, the high end of the range of $14 to $16. The company originally planned to offer 8.4 million shares...read more
Pediatric cancer biotech Day One Biopharma increases shares offered by 19% ahead of tonight's $150 million IPO
Day One Biopharmaceuticals, a Phase 2 biotech developing kinase inhibitors for pediatric brain tumors, raised the proposed deal size for its upcoming IPO on Wednesday. The South San Francisco, CA-based company now plans to raise $150 million by offering 10...read more
Pediatric oncology biotech Day One Biopharma sets terms for $126 million IPO
Day One Biopharmaceuticals, a Phase 2 biotech developing treatments for pediatric glioma and other cancers, announced terms for its IPO on Monday. The South San Francisco, CA-based company plans to raise $126 million by offering 8.4 million shares at a...read more